Australia is eagerly awaiting the introduction of Retatrutide, a novel medication by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, demonstrates remarkable performance in testing, https://keybookmarks.com/story22019597/novo-nordisk-s-retatrutide-australia-a-potential-hope-for-weight-management